Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, has scheduled the release of its first quarter 2025 financial results for Monday, May 19, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET where management will discuss the results and provide a corporate update. Investors can join via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through the company's website. A replay will be available on their website after the live event.
Compugen Ltd. (NASDAQ: CGEN), un'azienda in fase clinica specializzata in immunoterapia oncologica, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per luned矛 19 maggio 2025, prima dell'apertura dei mercati statunitensi. La societ脿 terr脿 una conference call e una webcast alle 8:30 AM ET durante le quali la direzione discuter脿 i risultati e fornir脿 un aggiornamento aziendale. Gli investitori potranno partecipare telefonicamente (USA: 1-866-744-5399, Internazionale: +972-3-918-0644) o tramite il sito web dell'azienda. Una registrazione sar脿 disponibile sul sito dopo l'evento in diretta.
Compugen Ltd. (NASDAQ: CGEN), una compa帽铆a en etapa cl铆nica dedicada a la inmunoterapia contra el c谩ncer, ha programado la publicaci贸n de sus resultados financieros del primer trimestre de 2025 para el lunes 19 de mayo de 2025, antes de la apertura de los mercados en EE. UU. La empresa realizar谩 una llamada conferencia y una transmisi贸n en vivo a las 8:30 AM ET, donde la direcci贸n discutir谩 los resultados y ofrecer谩 una actualizaci贸n corporativa. Los inversores podr谩n unirse por tel茅fono (EE. UU.: 1-866-744-5399, Internacional: +972-3-918-0644) o a trav茅s del sitio web de la compa帽铆a. Una repetici贸n estar谩 disponible en su sitio web tras el evento en vivo.
旎错摠鞝� Ltd. (NASDAQ: CGEN)鞚� 鞛勳儊 雼硠鞚� 鞎� 氅挫棴旃橂 須岇偓搿�, 2025雲� 1攵勱赴 鞛 瓴瓣臣毳� 2025雲� 5鞗� 19鞚� 鞗旍殧鞚� 氙戈淡 鞁滌灔 臧滌灔 鞝� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 霃欕秬鞁滉皠 旮办 鞓れ爠 8鞁� 30攵�鞐� 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃橂┌ 瓴届榿歆勳澊 瓴瓣臣毳� 雲检潣頃橁碃 須岇偓 順勴櫓鞚� 鞐呺嵃鞚错姼頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� 鞝勴檾(氙戈淡: 1-866-744-5399, 甑牅: +972-3-918-0644) 霕愲姅 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 靸濎瓿� 頉� 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
Compugen Ltd. (NASDAQ : CGEN), une soci茅t茅 en phase clinique sp茅cialis茅e dans l'immunoth茅rapie du cancer, a pr茅vu la publication de ses r茅sultats financiers du premier trimestre 2025 pour le lundi 19 mai 2025, avant l'ouverture des march茅s am茅ricains. La soci茅t茅 organisera une conf茅rence t茅l茅phonique et une webcast 脿 8h30 ET o霉 la direction discutera des r茅sultats et fournira une mise 脿 jour de l'entreprise. Les investisseurs pourront participer par t茅l茅phone (脡tats-Unis : 1-866-744-5399, International : +972-3-918-0644) ou via le site web de la soci茅t茅. Une rediffusion sera disponible sur leur site apr猫s l'茅v茅nement en direct.
Compugen Ltd. (NASDAQ: CGEN), ein klinisch fortgeschrittenes Unternehmen 蹿眉谤 Krebsimmuntherapie, hat die Ver枚ffentlichung seiner Finanzergebnisse 蹿眉谤 das erste Quartal 2025 蹿眉谤 Montag, den 19. Mai 2025 vor 脰ffnung der US-M盲rkte geplant. Das Unternehmen wird eine Telefonkonferenz und eine Webcast um 8:30 Uhr ET abhalten, bei der das Management die Ergebnisse besprechen und ein Unternehmensupdate geben wird. Investoren k枚nnen telefonisch (USA: 1-866-744-5399, International: +972-3-918-0644) oder 眉ber die Webseite des Unternehmens teilnehmen. Eine Aufzeichnung wird nach der Live-Veranstaltung auf der Webseite verf眉gbar sein.
- None.
- None.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the
or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following . Following the live webcast, a replay will be available on the Company's website.
础产辞耻迟听颁辞尘辫耻驳别苍
Compugen聽is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen鈩�) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,聽a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.聽GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage聽immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen聽is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
贰尘补颈濒:听[email protected]
Tel: +1聽(628)聽241-0071聽
View original content:
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release Q1 2025 earnings?
What time is Compugen's Q1 2025 earnings call?
How can I join Compugen's Q1 2025 earnings call?
Will there be a replay of Compugen's Q1 2025 earnings call?
